Related references
Note: Only part of the references are listed.Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2011)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Ethan Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification
Sun Och Yoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2010)
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ken Ohmachi et al.
CANCER SCIENCE (2010)
Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
Gaetano Corazzelli et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Bendamustine: Rebirth of an Old Drug
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents
Lorenzo M. Leoni et al.
CLINICAL CANCER RESEARCH (2008)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
K. Sue Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001-2006
Ryosuke Aoki et al.
PATHOLOGY INTERNATIONAL (2008)
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma:: a phase II study
Andres Lopez et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
T. El Gnaoui et al.
ANNALS OF ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
E Weidmann et al.
ANNALS OF ONCOLOGY (2002)
In vitro studies with bendamustine: Enhanced activity in combination with rituximab
MJ Rummel et al.
SEMINARS IN ONCOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
